Neurocrine Biosciences

top of page

SF Healthcare Week: Neurocrine Biosciences CEO Kyle Gano describes how the company's novel muscarinic agonist portfolio is rooted in novel drug design, with its lead M4 agonist in late-stage trials

Plus, how the neuroscience company has used its long history working with corticotropin releasing factor to move into obesity, with a project that acts on targets in the brain.

Company News

Jan 15

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page

SF Healthcare Week: Neurocrine Biosciences CEO Kyle Gano describes how the company's novel muscarinic agonist portfolio is rooted in novel drug design, with its lead M4 agonist in late-stage trials

Follow BiotechTV

Sponsors

Sponsor Spotlight